Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells

Breast Cancer Research and Treatment

Volumn 42, Issue 2, 1997, Pages 103-112

  Silvestrini, Rosella ^a   Gornati, Daniela ^a   Zaffaroni, Nadia ^a   Bearzatto, Alessandra ^a   De Marco, Cinzia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cell cycle; Chemotherapy; Cisplatin; Combination regimens; Drug resistance; Epidoxorubicin; Lonidamine; MCF7 cells; T47D cells

Indexed keywords

CISPLATIN; EPIRUBICIN; LONIDAMINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE PHASE; CELL STRAIN MCF 7; CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; EPIRUBICIN; HUMANS; INDAZOLES; TUMOR CELLS, CULTURED;

EID: 0031015908     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005725203159     Document Type: Article

References (25)

1. Silvestrini B, Palazzo G, De Gregorio M: Lonidamine and related compounds. Prog Med Chem 21: 111-135, 1984
2. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41: 4661-4666, 1981
3. 13C nuclear magnetic resonance studies. Cancer Res 55: 2814-2821, 1995
4. Szekely JG, Lobreau AU, Delaney S, Raaphorst GP, Feeley MM: Morphological effects of lonidamine on human tumor cells. Scand J Eleetr Microsc 3: 681-693, 1989
5. Malorni W, Meschini S, Matarrese P, Arancia G: The cytoskeleton as a subcellular target of the anti-neoplastic drug lonidamine. Anticancer Res 12: 2037-2046, 1989
6. Battelli T, Manocchi P, Guistini L: A long-term clinical experience with lonidamine. Oncology 41: 39-47, 1984
7. Hahn GM, vanKersen I, Silvestrini B: Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer 50: 657-660, 1984
8. Kim JH, Alfieri AA, Kim SH, Young CW: Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Res 46: 1120-1123, 1986
9. Zaffaroni N, Villa R, Orlandi L, Vaglini M, Silvestrini R: Combined effects of lonidamine and hyperthermia on malignant melanoma and lung carcinoma surgical specimens. Anticancer Res 12: 247-250, 1992
10. Rosbe KW. Brann TW, Holden SA, Teicher BA, Frei E: Effect of lonidamine on the cytotoxicity of four alkylating agents in vivo. Cancer Chemother Pharmacol 25: 32-36, 1989
11. Ning S, Hahn GM: Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro. Cancer Res 50: 7867-7870, 1990
12. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A: Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 52: 813-817, 1992
13. Citro G, Cucco C, Verdina A, Zupi G: Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 64: 534-536. 1991
14. Del Bufalo D, Zupi G: In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer cell line. Int J Oncol 4: 737-740. 1994
15. Dogliotti L, Berruti A, Buniva T, Zola P, Baú MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D: A randomized comparison of high dose epirubicin versus high dose epirubicin plus lonidamine in advanced breast cancer patients. First results from a cooperative group study, Int J Oncol 4: 747-752, 1994
16. Calabresi F, Marolla P, Di Lauro L, Gallo Curcio C, Paoletti G, Lombardi A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M, Stolfi R, Cortesi E: Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study, Int J Oncol 4: 753-760. 1994
17. Pacini P, Algeri R, Rinaldini M, Guarnieri A, Bastiani P, Barsanti G, Neri B, Marzano S, Tucci E: FEC (fluorouracil, epirubicin and cyclophosphamide) versus EM (epirubicin and mitomycin-C) with or without lonidamine as first line treatment for advanced breast cancer. A multicentric randomised study. Preliminary report, Int J Oncol 4: 761-766, 1994
18. De Lena M, De Mitrio A, Catino A, Lorusso V, Brandi M: Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results, Int J Oncol 4: 779-782, 1994
19. Gadducci A, Brunetti I. Muttini PF, Fanuechi A, Dargenio F, Giannessi PG, Conte PF: Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. Eur J Cancer 30A: 1432-1435, 1994
20. Soule HD, Vazques J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973
21. Keydar I. Chen L, Karby S, Weiss FR, Delarea M, Rachu M, Chaitek S, Brenner HJ: Establishment and characterization of a cell line of a human breast cancer origin. Eur J Cancer 15: 659-663, 1979
22. Drewinko B, Loo TL, Brown B, Gottlieb JA, Freireich EJ: Combination chemotherapy in vitro with adriamycin. Observation of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1: 187-195, 1976
23. Young CW, Currie VE, Kim JH, O'Hehir MA, Farag FM. Kinahan JE: Phase 1 and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer. Oncology 41: 60-65, 1984
24. Besner JG, Leclaive R, Band PR, Deschamps M, De Sanctis AJ, Catanese B: Pharmacokinetics of lonidamine after oral administration in cancer patients. Oncology 41 (Suppl 1): 48-52, 1984
25. laffaioli RV, Tortoriello A, Facchini G, Caponigro F, Mastrantonio P, Barzelloni ML, Gesué G, Mantovani G, Santangelo M: Recovery of sensitivity to cisplatinum and epidoxorubicin by lonidamine and Interferon in advanced ovarian cancer, Int J Oncol 4: 1265-1269. 1994